蛋白质组学在糖尿病肾病诊断及治疗中的应用研究进展  

Progress in the use of proteomics in the diagnosis and treatment of diabetic nephropathy

作　　者：邓林 王少清[1,2] 李萃萃 陈利佳 Deng Lin;Wang Shaoqing;Li Cuicui;Chen lijia(Nephrology Department,the First Affiliated Hospital of Chengdu Medical College,Chengdu 610500,China;Nephrology Department,the Second Affiliated Hospital of Chengdu Medical College/Nuclear Industry 416 Hospital,Chengdu 610051,China)

机构地区：[1]成都医学院第一附属医院肾内科,成都610500 [2]成都医学院第二附属医院·核工业416医院肾脏内科,成都610051

出　　处：《保健医学研究与实践》2022年第9期171-176,共6页Health Medicine Research and Practice

基　　金：四川省中医药管理局科研课题(2020LC0072);北京医卫健康公益基金会医学科研项目(YWJKJJHKYJJKH19007);成都市金牛区医学会2020年肾脏专项课题重点项目(JNZD20-12)。

摘　　要：糖尿病肾病是造成糖尿病患者高死亡率的主要原因之一,也是尿毒症的首要原因(占1/3)。糖尿病肾病进展快、疗效差,因此对有糖尿病并发症发展风险的个体进行早期诊断、预防进展及治疗指导极为重要。蛋白质组学在深入探究2型糖尿病的病理生理过程和调控机制方面发挥了重要作用,可用于识别有进展性肾脏疾病风险的个体和预期治疗效果良好的患者。目前已发现许多蛋白质组学生物标志物,但这些生物标志物大多反映糖尿病肾病终末期的疾病状态,缺乏早期诊断特异性和准确性。本文主要对糖尿病肾病潜在的蛋白质组学生物标志物、有肾脏疾病风险患者早期管理等方面文献进行综述,旨在为糖尿病肾病早期诊断及判断疾病进程提供新的思路。Diabetic nephropathy is one of the leading causes of high mortality in diabetic patients and the leading cause of uremia, accounting for one-third of uremia. Diabetic nephropathy progresses rapidly and has poor outcomes, so early diagnosis, prevention of progression, and treatment guidance are extremely important for individuals at risk of developing diabetic complications. Proteomics plays an important role in understanding the physiological processes and regulatory mechanisms of type 2 diabetes and can be used to identify individuals at risk of progressive kidney disease and those who respond well to treatment. Plenty of proteomic markers have been identified, but most of these biomarkers reflect the disease status of endstage diabetic nephropathy and lack early diagnostic specificity and accuracy. This paper reviews the potential proteomic markers of diabetic nephropathy and the early management of patients at risk of kidney disease in order to provide new ideas for the early diagnosis of diabetic nephropathy and determine the course of the disease.

关 键 词：蛋白质组学 糖尿病肾病 生物标志物 应用进展 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]